Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

ADHD drug shortage deepens as demand reaches new highs

By Brian Buntz | February 8, 2023

Adderall pills close up

[Image courtesy of Adobe Stock]

The national ADHD drug shortage has entered its fifth month, leaving people who rely on medications like Adderall with few alternatives. The shortage has also affected other drugs, including Concerta, Ritalin, and Vyvanse.

Factors contributing to the ADHD drug shortage

ADHD diagnoses have surged during the pandemic. The DEA limits the production of ADHD, which are Schedule II drugs with high abuse potential. Additionally, manufacturing and supply chain issues have also exacerbated the ADHD drug shortage. Generics giant Teva, for one, has acknowledged facing “intermittent manufacturing delays.”

There are also unclear guidelines for doctors pondering how long to prescribe ADHD drugs, according to Dr. Heidi Moawad, a neurologist on Sermo’s medical advisory board.

“Maybe the pharmaceutical companies will increase their production of [ADHD drugs], but I don’t know if that really is the only solution,” she said. “There’s also a need to have good guidelines for duration of treatment.”

Online telehealth companies like Cerebral and Done have faced criticism for prescribing ADHD drugs too liberally. In May 2022, Cerebral acknowledged it was under investigation by the Department of Justice (DOJ) for “possible violations” of the Controlled Substances Act. The DEA is also investigating Done for similar reasons.

The pandemic has also played a role

Moawad also noted that the pandemic played a role in ramping up demand for ADHD drugs.

The pandemic ramped up the use of telehealth, which can be used for assessing if patients have certain patient-reported symptoms. The pandemic-based decision to waive enforcement of the 2008 Ryan Haight Act made it possible to prescribe controlled substances via telehealth providers without requiring a physical exam.

The stress of the pandemic is another factor. “Experts seem to agree that ADHD symptoms can change depending on the environment,” Moawad said. And it is likely that the early days of the pandemic, when many people were stuck indoors, amplified ADHD symptoms and inspired some people to get a diagnosis.

Demand for stimulants also saw considerable growth before the pandemic. An article in PLOS One noted that prescription amphetamine use jumped 2.5 fold from 2006 to 2016. The article also noted that the U.S. consumes the bulk of ADHD drugs. In March 2020, the U.S. was consuming 83.1% of global Adderall supply. The U.S. has less than 5% of the world’s population.

There was also a shortage of amphetamine salt products in 2011, which includes products such as Adderall XR, Adderall and generics.

Some pharma companies now project that the current ADHD drug shortage will continue into spring.

In December 2022, U.S. Representative Abigail Spanberger called for the DEA to address the nationwide shortage of Adderall prescriptions. However, DEA decided against increasing manufacturing quotas for ADHD drugs in 2023, arguing that the drugs were overprescribed.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE